Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis

被引:0
作者
Qiu-Feng He
Qiong-Fang Zhang
Da-Zhi Zhang
机构
[1] Chongqing Medical University,Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital
来源
Digestive Diseases and Sciences | 2016年 / 61卷
关键词
Genotype 1 hepatitis C; Sofosbuvir; Ledipasvir; Ribavirin; Efficacy; Safety;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3108 / 3117
页数:9
相关论文
共 103 条
[1]  
Messina JP(2015)Global distribution and prevalence of hepatitis C virus genotypes Hepatology 61 77-87
[2]  
Humphreys I(2012)Natural history of acute and chronic hepatitis C Best Pract Res Clin Gastroenterol 26 401-412
[3]  
Flaxman A(2015)Screening for hepatitis C JAMA 313 1855-1856
[4]  
Maasoumy B(2015)Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence Liver Int 35 2433-2441
[5]  
Wedemeyer H(2011)Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006 Arch Internal Med 171 242-248
[6]  
Wray CM(2015)Interferon-free combination therapies for the treatment of hepatitis C: current insights Hepatic Med Evid Res 7 51-70
[7]  
Davis AM(2013)Ever closer to a prophylactic vaccine for HCV Expert Opin Biol Therapy 13 1109-1124
[8]  
Dhanasekaran R(2014)EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 60 392-420
[9]  
Sanchez W(2013)25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end Nat Rev Immunol 13 535-542
[10]  
Mounajjed T(2011)Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C Nat Rev Gastroenterol Hepatol 8 212-223